{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCV13", "query": { "intervention": "PCV13" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 47, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCV13&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T22:56:19.271Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00566098", "title": "Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "MILs", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "PCV13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2007-11", "completion_date": "2018-10", "has_results": true, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-09-03T22:56:19.271Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00566098" }, { "nct_id": "NCT03530124", "title": "Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Apnea", "Apnea Neonatal", "Prematurity" ], "interventions": [ { "name": "PCV13", "type": "BIOLOGICAL" }, { "name": "DTaP", "type": "BIOLOGICAL" }, { "name": "HBV", "type": "BIOLOGICAL" }, { "name": "IPV", "type": "BIOLOGICAL" }, { "name": "Hib", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": null, "sex": "ALL", "summary": "6 Weeks and older" }, "enrollment_count": 223, "start_date": "2018-07-17", "completion_date": "2021-11-01", "has_results": true, "last_update_posted_date": "2024-02-14", "last_synced_at": "2026-09-03T22:56:19.271Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Chapel Hill, North Carolina • Durham, North Carolina + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03530124" }, { "nct_id": "NCT01214837", "title": "Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Meningococcal Disease", "Meningococcal Meningitis" ], "interventions": [ { "name": "MenACWY-CRM", "type": "BIOLOGICAL" }, { "name": "Routine Vaccines", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Vaccines", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "55 Days", "maximum_age": "89 Days", "sex": "ALL", "summary": "55 Days to 89 Days" }, "enrollment_count": 751, "start_date": "2010-10", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-09-03T22:56:19.271Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01214837" }, { "nct_id": "NCT03803202", "title": "A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pneumonia, Bacterial", "Healthy Volunteers", "Pneumococcal Disease" ], "interventions": [ { "name": "ASP3772", "type": "BIOLOGICAL" }, { "name": "PCV13", "type": "BIOLOGICAL" }, { "name": "PPSV23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 630, "start_date": "2019-01-24", "completion_date": "2020-09-28", "has_results": true, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-09-03T22:56:19.271Z", "location_count": 26, "location_summary": "Banning, California • San Diego, California • San Marcos, California + 21 more", "locations": [ { "city": "Banning", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03803202" }, { "nct_id": "NCT01527591", "title": "Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Infection in Solid Organ Transplant Recipients" ], "interventions": [ { "name": "Pneumococcal Conjugate Vaccine 13 (PCV13)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "59 Months", "sex": "ALL", "summary": "12 Months to 59 Months" }, "enrollment_count": 17, "start_date": "2012-02-01", "completion_date": "2025-12-30", "has_results": false, "last_update_posted_date": "2025-04-02", "last_synced_at": "2026-09-03T22:56:19.271Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01527591" }, { "nct_id": "NCT02309515", "title": "Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Monoclonal B-Cell Lymphocytosis", "Stage 0 Chronic Lymphocytic Leukemia", "Stage I Chronic Lymphocytic Leukemia", "Stage I Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pneumococcal 13-valent Conjugate Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2015-06-11", "completion_date": "2017-07-21", "has_results": true, "last_update_posted_date": "2021-01-19", "last_synced_at": "2026-09-03T22:56:19.271Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02309515" }, { "nct_id": "NCT02049138", "title": "An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Pneumococcal 13-valent conjugate vaccine (PCV-13)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 493, "start_date": "2014-01-24", "completion_date": "2021-07-29", "has_results": true, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-09-03T22:56:19.271Z", "location_count": 52, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 44 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hemet", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02049138" }, { "nct_id": "NCT01702428", "title": "Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rubella", "Measles", "Mumps" ], "interventions": [ { "name": "Priorix", "type": "BIOLOGICAL" }, { "name": "M-M-R II", "type": "BIOLOGICAL" }, { "name": "Varivax", "type": "BIOLOGICAL" }, { "name": "Havrix", "type": "BIOLOGICAL" }, { "name": "Prevnar 13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 5016, "start_date": "2012-11-09", "completion_date": "2015-04-16", "has_results": true, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-09-03T22:56:19.271Z", "location_count": 62, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 56 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Daly City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01702428" }, { "nct_id": "NCT03260790", "title": "Pneumococcal Vaccines in Patients With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "PCV13", "type": "BIOLOGICAL" }, { "name": "PPSV23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "19 Years to 64 Years" }, "enrollment_count": 17, "start_date": "2017-10-01", "completion_date": "2020-12-25", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-09-03T22:56:19.271Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03260790" }, { "nct_id": "NCT02851056", "title": "Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Survivin Vaccine", "type": "BIOLOGICAL" }, { "name": "Autologous Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Prevnar 13", "type": "BIOLOGICAL" }, { "name": "Granulocyte-colony Stimulating Factor", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2016-09-27", "completion_date": "2018-08-09", "has_results": false, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-09-03T22:56:19.271Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02851056" } ] }